Pfizer’s shares dropped steeply on Tuesday as global markets rose steadily. Analysts lowered estimates for the firm over a thin pipeline. Some investors worry the pipeline appears limited and leadership remains unsettled.
But Pfizer secured a key approval: the first CDK4/6 maintenance therapy for advanced HER2-positive breast cancer. However, the stock losses overshadowed the good news. Offices in Midtown Manhattan cleared out after beams gave way, triggering collapse concerns.